20th Mar 2023 11:21
(Alliance News) - Aptamer Group PLC on Monday expanded its Optimer binder pipeline with the launch of Optimer-Fc, a new reagent solution for immunohistochemistry.
Aptamer is a York, England-based company which develops custom affinity binders through its proprietary Optimer platform to enable new approaches in therapeutics, diagnostics and research applications.
Optimer binders can function as an antibody alternative. Optimer-Fc tools consist of an Optimer binder conjugated to the Fc domain of an antibody.
"Our new Optimer-Fc meets an urgent need for the IHC market to develop new patentable reagents. Over the past several months, we have innovated to support this market need, and developed and validated our new platform to develop these reagents. We have already seen keen interest from major companies within the IHC space and top pharma," said Chief Executive Officer Arron Tolley.
"We are now actively working with these partners to supply and support them in the use of Optimer-Fc. Optimer-Fc offers the ability to pursue new targets, that have proven previously intractable with antibodies, and improve assay selectivity. We anticipate this will open up further opportunities for emerging biomarkers in research and diagnostics, which could further increase the potential of our new IHC tools."
Aptamer shares were flat at 28.00 pence each in London on Monday morning.
By Holly Beveridge, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
Aptamer Group